COVID-19 studies for: C19 studies:  HC QHC Q IvermectinIVM Vitamin DVitamin D ZincZn REGN-COV2REGN LY-CoVLY RemdesivirRMD
HC Q study #94
Source   PDF   Share   Tweet
See all 181 studies
7/28
Inconc.
Late treatment study
Ba┼×aran et al., Turk. J. Med. Sci., doi:10.3906/sag-2006-173 (Peer Reviewed)
Outcome of Non-Critical COVID-19 Patients with Early Hospitalization and Early Antiviral Treatment Outside the ICU
Observational study of 174 hospitalized patients in Turkey, median age 45.4, 23 treated with HC Q, 113 with HC Q+AZ, and 32 with regimens including favipiravir. 75% reduction in the median time to clinical improvement for HC Q+AZ vs. FAV, RR 0.25, p<0.001. 83% reduction for HC Q. However, there was significant confounding by indication.
There were no significant adverse events.
Source   PDF   Share   Tweet
See all 181 studies
Please send us corrections, updates, or comments.
Submit